Abeona Therapeutics Inc (NASDAQ:ABEO) had its Buy rating reiterated by HC Wainwright with a $15.00 price target

Abeona Therapeutics Inc (NASDAQ:ABEO) is Buy with a consensus target price of $19.67 per share, a potential 625.71% upside.

Some recent analyst ratings include

• 10/16/2019-
  Abeona Therapeutics Inc (NASDAQ:ABEO) had its Buy rating reiterated by HC Wainwright with a $15.00 price target
• 9/23/2019-
  Abeona Therapeutics Inc (NASDAQ:ABEO) had its Hold rating reiterated by Mizuho with a $4.00 price target
• 8/15/2019-
  Abeona Therapeutics Inc (NASDAQ:ABEO) gets downgraded to Hold by Maxim Group
• 8/12/2019-
  Abeona Therapeutics Inc (NASDAQ:ABEO) gets downgraded to Neutral by Cantor Fitzgerald
• 6/27/2018-
  Abeona Therapeutics Inc (NASDAQ:ABEO) has coverage initiated with a Buy rating and $26.00 price target

  • On 4/11/2019 Stefano Buono, Director, bought 70,000 with an average share price of $7.80 per share and the total transaction amounting to $546,000.00.
  • On 4/8/2019 Stephen B. Howell, Director, bought 4,000 with an average share price of $7.77 per share and the total transaction amounting to $31,080.00.
  • On 9/20/2016 Todd Wider, Director, bought 5,000 with an average share price of $5.48 per share and the total transaction amounting to $27,400.00.
  • On 7/31/2015 Mark J Ahn, Director, bought 18,182 with an average share price of $5.50 per share and the total transaction amounting to $100,001.00.
  • On 1/26/2015 Mark J Ahn, Director, bought 25,000 with an average share price of $4.00 per share and the total transaction amounting to $100,000.00.
  • On 12/24/2014 Steven H Rouhandeh, Director, bought 250,000 with an average share price of $4.00 per share and the total transaction amounting to $1,000,000.00.

  Recent Trading Activity for

  Abeona Therapeutics Inc (NASDAQ:ABEO)
  Shares of

  Abeona Therapeutics Inc closed the previous trading session at with shares trading hands.

  Exit mobile version